Blood Cancer Patient Thrives 8 Years After Trial

A grandfather given two years to live is celebrating eight years of life after joining a groundbreaking cancer trial that changed everything.

Ken Theobold was 68 when doctors diagnosed him with high-risk myeloma, an aggressive blood cancer that kills plasma cells. The news was devastating: conventional treatments wouldn't work for his type of cancer.

But Ken made a choice that saved his life. He signed up for a trial testing personalized medicine combinations at The Institute of Cancer Research in London.

"Joining the trial was an absolute no-brainer," Ken said. "If there was a chance it could help me and help future patients, I wanted to be part of it."

The trial started Ken on five different drugs already used in the NHS, but doctors gave them in a new way. They hit the cancer hard at the start, then continued combination therapy for as long as it worked. Ken now takes just two drugs and feels great.

The results are stunning. After six years, 70 percent of trial patients were still alive compared to just 40 percent on standard treatment. More than half remained cancer-free, compared to only 18 percent with usual care.

The secret? Matching treatment to each person's unique cancer biology. Researchers used genetic tests to identify which patients had the most aggressive forms and needed the most intensive treatment.

The Ripple Effect

This breakthrough matters beyond Ken's story. About 5,900 people get multiple myeloma diagnoses each year in the UK, and a quarter don't respond to conventional treatment. This personalized approach could transform their outcomes too.

The challenge now is access. The genetic test that identifies high-risk patients isn't routinely available in the NHS yet, meaning some aggressive cases get missed. Health regulators are currently evaluating it for wider use across the health service.

Professor Martin Kaiser, who led the study, put it simply: "High-risk myeloma has traditionally been one of the toughest challenges we face. These results show that when we adapt treatment to the biology of the disease, we can significantly extend survival for patients who previously had very limited options."

Today, Ken is living proof that understanding cancer at the molecular level can outsmart even the deadliest forms. He spends his days traveling with his wife Brenda in their motorhome and making memories with their five grandchildren.

Eight years after being told he had two left, Ken is making every moment count.